Raymond James analyst Christopher Raymond upgraded Regeneron (REGN) to Outperform from Market Perform with a $673 price target after assuming coverage of the name. The firm believes Eylea’s potential upside is not being priced into the shares. Raymond James’s new survey work indicates Regeneron’s overall patient share remains dominant with “robust” Eylea HD growth potential, the analyst tells investors in a research note. It sees numerous sources of upside to the shares from Eylea upside and Dupixent’s continued strength.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron’s Phase 2 Study on Blood Clot Prevention: A Potential Game-Changer?
- Regeneron’s Heart Failure Study: A Potential Game-Changer?
- Regeneron and Sanofi’s DUPIXENT® Study: A Closer Look at EoE Treatment
- Regeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in Thromboprophylaxis
- Regeneron’s Promising Study on REGN7999 for Iron Overload in Beta-Thalassemia